Food, Global Health 2 min

Non-hormonal female contraception using antibody fragments

PRESS RELEASE - Accelerating Discovery for Non-Hormonal Contraceptives is one of the Grand Challenge programmes launched by the Bill & Melinda Gates Foundation for the coming years. A research project has just started in the context of this programme, having received funding worth $1.8 million. The project is being managed by a consortium led by INRAE and involving IN-CELL-ART, a French biotechnology company specialised in nanotransporter technologies called NANOTAXI®, the Italian university UNIMORE [1] , and MAbSilico, an INRAE start-up that proposes software based on artificial intelligence technologies for the development of antibodies. The aim is to design biological products based on antibody fragments to block ovulation and thus enable non-hormonal contraception that causes fewer adverse effects.

Published on 22 March 2021

illustration Non-hormonal female contraception using antibody fragments

In this collaborative project, the INRAE research team[2], which specialises in studying the membrane receptors that control reproduction, is focusing in particular on the contraceptive mechanism that blocks the molecular regulators of ovulation. Antibody fragments that target receptors present in ovarian cells can very selectively modulate the effects of natural hormones within these cells. Studies will aim to develop antibody fragments that can selectively block ovulation without disturbing the endogenous production of steroid hormones. These antibody fragments will then be modified to produce sufficiently durable effects to guarantee contraception, while ensuring the reversibility of the ovulation blockade after treatment is discontinued. 

The software platform developed by MAbSilico is being used for the selection, characterisation and optimisation of antibody fragments that target the regulators of ovulation. The artificial intelligence technology developed by this biotech firm enables the digitisation of antibody discovery, accelerating and securing this critical step.

Best antibodies will be selected in vitro by UNIMORE, where they will be tested using human ovarian cells. This working package is fundamental to ensure the functionality of antibodies in humans and relies on the expertise of its Unit of Endocrinology in hormonal regulation of the reproductive functions.

The antibody fragments thus optimised will then be tested in vivo in mice by administering synthetic non-inflammatory mRNA coding for this new class of biologics. This will trigger the production of antibody fragments by the mouse’s muscle fibres, their secretion into the blood and finally their action on the ovaries. This technology, called NANOTAXI®, will thus make it possible to avoid the bioproduction of antibody fragments, which is cumbersome, expensive and lengthy. The most promising antibody fragments will then be tested non-invasively in ewes.[3]

[1] Università degli studi di Modena e Reggio Emilia

[2] Associated with the MAbImprove LabEx dedicated to therapeutic antibodies.

[3] By the platforms operated by the Val de Loire INRAE Research Centre at the L’Orfrasière Animal Physiology Experimental Unit and Pixanim (INRAE Université François-Rabelais and Tours University Hospital).


Learn more


Organic farming favours pest regulation

PRESS RELEASE - Scientists from INRA, Université de Rennes 1 and their colleagues have demonstrated that organic farming favours the natural regulation and control of pests – pathogens, insects and weeds. These results, published in Nature Sustainability on 16 July 2018, offer interesting perspectives in terms of reducing the use of synthetic pesticides.

09 March 2020